Second Genome has announced a deal with Pfizer to conduct a large microbiome observational study to find out more about obesity and metabolic diseases.
The study is aimed at evaluating clinical factors and the microbiome in a cohort of about 900 individuals with various metabolic phenotypes in order to elucidate the interrelationship between the microbiome, obesity, and metabolic disorders.
— UPCOMING EVENTS —
5/12 5:00 pm – 6:30 pm in New Haven
BioScienceClubhouseCT presents ‘SystaMedic: A Novel Cause-Effect Analysis Platform for Predicting Probability of R&D Program Success’ … more
5/14 9:00 am – 4:00 pm in New Haven
Diabetes Symposium: “Innovative Approaches to Diabetes Research and Therapies” … more